Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Up 7.2 %

Shares of PULM opened at $6.86 on Friday. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $8.44. The stock has a market capitalization of $25.05 million, a P/E ratio of -2.60 and a beta of 1.54. The company has a 50 day moving average of $4.69 and a 200-day moving average of $2.99.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.